NCT06801106 is a NA clinical trial of Acapella in Chronic Obstructive Airway Disease, sponsored by Ministry of Health and Population, Egypt.

Who is sponsoring NCT06801106?

NCT06801106 is sponsored by Ministry of Health and Population, Egypt.

What drugs are being tested in NCT06801106?

Interventions in NCT06801106: Acapella, Lung flute.

What condition does NCT06801106 study?

NCT06801106 studies Chronic Obstructive Airway Disease.

Is NCT06801106 still recruiting?

NCT06801106 is currently completed. Last updated 30 January 2025.

Last reviewed 2025-01-30 · How we verify

NCT06801106

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acapella Versus Lung Flute in Treatment of COPD Patients the Study Aims to Identify the Preference Between the Two Devices According to Treatment of COPD Patients Regarding Pulmonary Function Tests , Exercise Tolerence and Quality of Life Questionnaire,

Completed NA Last updated 30 January 2025

What this trial tests

NA trial testing Acapella in Chronic Obstructive Airway Disease in 70 participants. Completed in 20 January 2024.

Timeline

31 January 2021

Primary endpoint
20 January 2024

20 January 2024

Quick facts

Lead sponsor	Ministry of Health and Population, Egypt
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	70
Start date	31 January 2021
Primary completion	20 January 2024
Estimated completion	20 January 2024
Sites	1 location across Egypt

Drugs / interventions tested

Acapella
Lung flute

Conditions studied

Chronic Obstructive Airway Disease — all drugs for Chronic Obstructive Airway Disease →

Sponsor

Ministry of Health and Population, Egypt

Who can join

Adults 40 to 60, male only, with Chronic Obstructive Airway Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chronic obstructive pulmonary disease (COPD) is a prevalent and progressive condition characterized by persistent airflow limitation and chronic respiratory symptoms. Among the many approaches to managing COPD, airway clearance techniques (ACTs) play a pivotal role in improving pulmonary function, reducing symptoms, and enhancing quality of life. So, this study aimed to investigate the comparative efficacy of two ACT devices-the Acapella® and the Lung Flute®- on improving pulmonary function, exercise capacity, and quality of life in COPD patients. The Acapella® and the Lung Flute®. Both devices utilize distinct mechanisms to facilitate mucus clearance and improve lung function. The Acapella® combines positive expiratory pressure (PEP) with oscillatory vibration, aiding in the loosening and mobilization of mucus . On the other hand, the Lung Flute® generates low-frequency sound waves through patient exhalation, stimulating mucus movement from the peripheral to central airways . While both devices have demonstrated efficacy in previous studies, there is limited comparative research evaluating their impact in COPD patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Chronic Obstructive Airway Disease

Currently open trials in the same condition.

NCT06629675 — Make Every Step Count: Personalised Music Feedback to Walking for People Living With COPD · NA · recruiting

Other Ministry of Health and Population, Egypt trials

Trials by the same sponsor.

NCT06148805 — Effect of Pilates Exercises and Diaphragm Manual Therapy Techniques in Rotator Cuff Tendinopathy · NA · unknown
NCT06002256 — Mostafa Maged Maneuver in Comparison With Bimanual Uterine Compression to Control Post-partum Hemorrhage · NA · completed
NCT06159959 — Carbetocin in the Prevention of Primary Postpartum Haemorrhage · completed
NCT04425707 — Ivermectin In Treatment of COVID 19 Patients · NA · unknown
NCT04816942 — Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06801106 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ministry of Health and Population, Egypt
Last refreshed: 30 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06801106.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing